Healthcare Resource Utilization, Healthcare Costs, and Dose Escalation in Psoriasis Patients Initiated on Ustekinumab versus Adalimumab: A Retrospective Claim Study

Journal of Dermatological Treatment, 2016 10: 1-23. doi: 10.1080/09546634.2016.1247946

Adalimumab and ustekinumab are effective psoriasis treatments. This study compares healthcare resource utilization (HRU), costs and dose escalation, and describes starting dose trends in ustekinumab versus adalimumab psoriasis patients.

View abstract

Authors

Wu JJ, Guerin A, Gauthier G, Sundaram M